Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Ann N Y Acad Sci. 2023 Aug;1526(1):16-29. doi: 10.1111/nyas.15012. Epub 2023 Jul 3.
Nonalcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease worldwide and a leading indication for liver transplantation in the United States. NAFLD encompasses a heterogeneous clinicopathologic spectrum, ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis, and progressive fibrosis, which can lead to end-stage liver disease including cirrhosis and hepatocellular cancer. Predictive models suggest that over 100 million adults in the United States will have NAFLD by 2030, representing over a third of the population. In this manuscript, we provide an overview of NAFLD risk factors, natural history (including hepatic and extra-hepatic outcomes), diagnosis, and current management strategies.
非酒精性脂肪性肝病（NAFLD）现已成为全球最常见的慢性肝病，也是美国肝移植的主要指征。NAFLD 包含一个异质的临床病理谱，从非酒精性脂肪肝（NAFL）到非酒精性脂肪性肝炎，以及进行性纤维化，可导致终末期肝病，包括肝硬化和肝细胞癌。预测模型表明，到 2030 年，美国将有超过 1 亿成年人患有 NAFLD，占人口的三分之一以上。在本手稿中，我们提供了 NAFLD 危险因素、自然史（包括肝脏和肝脏外结局）、诊断和当前管理策略的概述。
